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Summary.-During a population-based screening project for breast cancer, almost
15,000 women aged 50 years and over have provided a 12 h (overnight) sample of urine
for research purposes. In 3,789 women the excretion of 11-desoxy-17-oxosteroids
(DOOS) and creatinine was measured. Results were analysed in terms of urinary
concentrations and of a ratio between DOOS and creatinine.
Age had an effect on DOOS, creatinine and their ratio. Body weight and body
surface area had an effect on creatinine excretion and therefore on the ratio.
The following variables did not have an appreciable effect on the above-mentioned
ratio: a family history of breast cancer, parity and age at first pregnancy, menopause
and oestrogenic drugs, and parenchymal pattern of the breast as observed on the
xeromammogram.
Breast cancer was found at first screening in 106 out of14,697 women. In 100 ofthese
cases DOOS and creatinine were measured. Excretion values expressed as the ratio
between the two, allowing for body surface area, did not differ materially from those
of 100 age-matched controls.
These results lead the authors to the conclusion that the determination of androgen
metabolite excretion in women over 50 years of age is of no help in selecting a group
at high risk of breast cancer.
EXTENSIVE WORK by Bulbrook et al.
(1962) has drawn attention to the impor-
tance of androgen-metabolite excretion
in the treatment of advanced breast
cancer. These investigators also ventured
the hypothesis that abnormal androgen
metabolism might be of predictive value
in assessing which women are at high risk
of this disease. In 1961 they set up a pros-
pective study on the island of Guernsey
and collected 24h specimens of urine in
over 5000 women. After a period of 10
years they published the findings in 27
women who had developed mammary
cancer since the inception of the study,
comparing them with a large number of
controls. They concluded that low andro-
gen-metabolite excretion might indicate a
higher than normal risk of developing the
disease (Bulbrook et al., 1971).
On several occasions Bulbrook and co-
workers expressed hope that determina-
tion of androgen metabolites in the urine
might help in defining a high risk group
when screening for breast cancer in a
population (see Farewell (1977) and Fare-
well et al. (1978)). We took up this point
when we designed a large population
study for the early detection of breast
cancer in the city of Utrecht and its
suburbs. Our aim was not only to test the
predictiveness of 11-desoxy 1 7-oxosteroid
(DOOS) excretion in respect of breast
cancer, but also to explore its possible
relationships with known risk factors of
this disease.
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MATERIAL AND METHODS
The early-detection study was designed
after the success of combined physical ex-
amination and mammography in women over
50 years of age had been published by
Shapiro et al. (1971) from the Health Insur-
ance Plan ofGreater New York. After having
obtained funds from the Prevention Fund,
the Ministry of Health and the National
Cancer Campaign (Queen Wilhelmina Fund),
a team of the University of Utrecht set up a
detection centre in the new business and
administrative district of the city ofUtrecht,
just opposite the Central Railway and Bus
Station, so that public transport facilities,
were met.
With the co-operation ofmunicipal authori-
ties the total female population of Utrecht
(and later also the suburban women) was
invited street by street. During 1975,
1976 and the first half of 1977 14,697 women
aged 50-66* (i.e. born 1911-1925) were in-
vestigated; the response rate for the first
examination was 72%.
The investigation not only had immediate
public health aims but also scientific ones. It
is our belief that such large-scale under-
takings should be used to learn more about
the natural history of the disease. Thus the
investigation comprised not only physical
examination of the breasts and mammo-
graphy (xeroradiography) but also a ques-
tionnaire with a number of items of epi-
demiological interest and a few somatometric
measurements for assessing nutritional status.
In addition we asked the women to bring
with them a bottle containing all urine col-
lected from 8 pm on the previous day until
after the first urine of the day of screening;
99.2% of women actually complied with our
request.
From each urine specimen 2 samples of
250 ml were taken, frozen at -20°C, sealed in
plastic bags and stored under a unique
identification number at that temperature in
a large refrigerating room outside the city.
From time to time samples were brought into
the small laboratory of the Preventicon
Centre for the semi-automated determination
of DOOS (by the method described by
Rademaker et al., 1976) and creatinine (Cr)
(based on an automated Jaff6 reaction).
Following a suggestion by Miller et al.
(1967) we measured total DOOS rather
than one or more of the individual DOOSS,
such as aetiocholanolone, androsterone or
dehydroepi-androsterone.
The rationale of measuring creatinine was
the immediate consequence of our decision to
limit the urine collection period to about 12 h.
It was thought too much of a burden for the
women to collect 24h specimens. Thus, the
results of DOOS determination were cal-
culated in mg/l and also in terms of a DOOS/
Cr ratio.
In order to justify the latter procedure a
pilot study was carried out by asking a
number of women to provide not only the
urine voided between 8 pm and 8 am (over-
night urine) but also the following specimens
until 8 pm (day urine). The results from this
sample of 44 women were as follows:
1. The (Pearson) correlation coefficient
between the DOOS/Cr ratio during the
night and the excretion of DOOS per
24 h was 0'95.
2. The correlation coefficient between the
DOOS/Cr ratio during the night and the
excretion of DOOS per 24 h was 0X72.
This implies that about half the varia-
tion of the latter can be "explained"
statistically by the ratio during the
iiight (Fig. 1).
3. The spread in Cr excretion values could
not be reduced substantially by intro-
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Fioe. 1. Correlation between DOOS/Cr in a
12h overnight specimen of urine and
DOOS excretion per 24 h (r=0.72).
* The discrepancy between age range and year-of-birth range is due to the fact that it took 21 years to
screen the total cohort ofwomen. In various tables we refer to the oldest group as aged 50-64 years.
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ducing parameters of body size or fat-
free body mass.
XVe concluded that the DOOS/Cr ratio in
the overnight samples of urine could be iused
as a measure of androgen-metabolite ex-
cretion.
Since the number of urine specimens far
exceeded the capacity of our laboratory, the
following plani was made.
The intake of women in the study was
divided into 5 successive study cohorts
numbered I-V. Cohort I had its initial ex-
ainination during the first half of 1975,
Cohort II during the second half of 1975, etc.
In Cohort I all urines (n=2171) were ex-
amined. From Cohorts II-IV 2 sets of
samples were studied:
1. A randomly selected group (n 790)
matched by day of screening, with
2. A compound high-risk group consisting
of women Aith one or more risk factors
(n=828) such as previous history of
breast biopsy, family history of breast
cancer, late age at first pregnancy comn-
bined with definite overweight.
Moreover, the 12h urine specimeni of 100/
106 women found to have mammary cancer
through our screening effort could beanalysed.
An interesting feature of such a series is
that the outcome can be equated more or less
to a prospective study, since cancers N-ould
have been found later (and in a different time
order) if screening had niot been carried out.
Thus, in a way we had found an economic
means of repeating the Guernsey study,
thouigh in a somewrhat older groul) of w-oien.
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RESIULTS
Possible relationships between DOOS/Cr
ratio and known riskfactors ofbreast cancer
Age. The effect of age on DOOS
excretion is well known from (inter alia)
Bulbrook's studies. Within the fairly small
age interval of our study a decreasing
trend ofthe DOOS/Cr ratio withincreasing
age can be seen (Table I). Separateanalyses
of DOOS and Cr excretion (expressed per
litre) show that the androgen-metabolite
excretion decreased somewhat faster than
Cr excretion with age (Fig. 2). Thus, in
analysing the effect of other determinants
it has been necessary to control for age.
Family history of breast cancer.-Each
woman was questioned regarding mast-
ectomy in her mother and/or sister(s). We
accepted a history of mastectomy at face
TABLE I.-Effect of age on ratio of
DOOS and creatinine excretion (DOOS/
Cr). Cum tlative per cent distribution and
total number of women investigated in
Cohort I.
DOOS/Cr
<2
2--29
3-3 9
4-4 '3
4 4.;() 5 59.
-,7
Age
50-54 55-59
(ii ---1008) (n 687)
3-1 4.9
25)-4 29 4
58 8 62-2
818f 83-5
91-5 93-7
96-0 97-2
10W0 1000
50 51 52 53 54 55 56 57 58 59 60 61 C2 63 64 65
AGE
60-64
(in =476)
5-3
35-6
67-1
88-9
95-8
97.3
1000(
60
50
40 - 0)
30
20
10
Fr(. 2. Percentages of an(drogen-metabolite (DOOS) concentration in urinie >4 mg/I aind of urinary
concentration of creatinine > I g/l according to age. 0, DOOS; O, Cr.ANDROGEN METABOLITES IN WOMEN 691
TABLE II.-Numbers of women investigated, those with a family history of mastectomy
(probands) vs controls
Cohort I Random "High risk" Total
Mother A ,
mastectomy Pro- Con- Pro- Con- Pro- Con- Pro- Con-
vs controls bands trols bands trols bands trols bands trols
50-54 30 939 10 258 75 137 115 1334
55-59 22 630 11 250 81 110 114 990
60-64 19 429 7 219 ,53 109 79 757
50 64 71 1998 28 727 209 356 308 3081
Sister
mastectomy
?'s controls
50-54
55 -59
60 64
50-64
34
35
27
96
721
483
332
1536
8
11
11
30
204
200
179
583
78
93
85
256
96
88
92
276
120
139
12:3
382
1021
771
603
2395
Differences in total numbers of controls from total numbers mentionedl in the text are due to deliberate
omissioin of women with unknown family history. Differences between controls of "mother series" and
controls of "sistel series" are due to deliberate omission of those women from the latter series wxho had no
sisters. Control groups have a negative family history of breast cancer for both mothers and sisters.
value, since in a previous study (de Waard
et al., 1964) we had found that mastectomy
almost always meant breast cancer.
The analysis was carried out on an age-
%cum
100
75
5o
25
stectomy (n=120)
i=1021 )
p>/ age 50-54
/*- mother mastectomy (n=l 15)
O-o control (n=1334 )
2 3 4 5 6 7 i7
DOOS/Cr
Fie. 3.-Cumulative frequency (listributions
of DOOS/Cr in women aged 50-54 years
with a sister or a mother having undergone
mastectomy an(1 in controls.
specific basis, separating Cohort I from
Cohorts II-IV initially, and later combin-
ing them. In studying the distributions of
DOOS/Cr ratios the population of women
with mastectomized sister(s) was com-
pared with other women having sisters.
As controls for those with a history of
mastectomy in their mothers, all other
women with no such family history (from
Cohort I or the random sample of Cohorts
II-IV) were used.
The numbers of women investigated are
summarized in Table II, and the results
in women aged 50-54 are shown in Fig. 3.
The conclusion is entirely negative, in
that we found no differences between
those with a family history of mastectomy
and controls. The same conclusion was
reached for those aged 55 and over.
Since the sample is unbiased and its
size is large, we are inclined to believe that
this result, which adds the older age range
to a smaller study by Bulbrook (1972), is
definite.
Parity and age at first pregnancy. In
the analysis we have distinguished the
nulliparous from the parous. In the former
the unmarried have been separated from
the ever-married women, and in the parous
a division has been made between those
who gave birth to their first child before
and after 30 years ofage respectively. The
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TABLE III. DOOS/Cr ratio according to
marital status, parity and age at first
birth, by age. Cross-sections from cumula-
tivefrequency distributions (Cohort I and
random sample of Cohorts II-IV7)
Age
(yrs)
50-54 Unmarried
AMarried no
child
Age at 1st
birth
<30
>30
55-59 Unmarried
Marriedl no
child
Age at 1st
birth
<30
>30
60-64 Unmarried
Married no
child
Age at 1st
birth
<30
>30
results are shown ir
cross-sections from
tributions are prese
ences in the DOOS/4
A more detailed
of age at first birth i
also shows no clear I
Menopause and of
sis has been limite
years of age. In th
substantial proporti
yet reached the men
TABLE IV. Cross-s8
lative frequency di
of women accordii
(Cohort 1) 50-54
DOOS/Cr <3 and
Age at Ist No. c
birth WOmE
<21 64
22-23 77
24-25 163
26-27 163
28--29 123
> 30 207
Total 797
No. of
womerl
studied
112
127
769
271
75
87
604
193
77
% with DOOS/Cr
<3 <4
26-8 57.1
23-6 55.9
27-2
22-1
26-7
34-5
60-6
56-8
61-3
67-8
32-6 64-1
26-9 59-1
32-5 66-2
TABLE V. Effect of menopause and oestro-
gens. Cross-sections from the cumulative
distributions of women (Cohort I) 50-54
and 55-59 years of age, with percentages
of women having DOOS/Cr <3 and
<4 respectirely
% with DOOS/Cr
No. of
women <3 <4
Age 50-54 yrs
Premenopausal
on oestrogenic drugs* 74 28-5 60-9
not on oestrogens 369 24-7 59.1
Postmenopausal
not on oestrogens
(menopause natural) 315 24-1 57-1
menopause artificial 161 26-1 60-9
on oestrogen drugs 89 30 4 59-6
Age 55-59 yrs
Total cohort 687 29-4 62-2
On oestrogenic drugs 57 28-1 59-7
* Inclucling contraceptive pill.
79 32-9 73-4 In the postmenopausal group a distinc-
tion between natural and artificial meno-
387 37-2 67-7 pause has been made; in those on oestro-
169 39-6 68-6 gens (n 89) the proportion of excretion
values (DOOS/Cr ratio) lower than 3 is
Table III, in which slightly but not significantly increased,
the cumulative dis- and this trend is not seen in those aged
nted. No clear differ- 55s59.
Cr ratio are apparent. Weight, height, overweight (Quetelet's index)
analysis of the effect and body-surface area (as estimated from
in Cohort I (Table IV) weight and height). In analysing the effect
trend. ofthese variables some conspicuous trends
?strogens. The analy- become apparent; viz. a tendency to lower
d to those under 60 values of the DOOS/Cr ratio with increas-
[e 50-54 age group a ing body weight (and variables derived
on of women has not from it). This prompted us to analyse these
iopause (Table V). effects (of weight etc.) on DOOS and Cr
urinary concentrations separately. Neither
?ctions from the cumu- weight nor height had a clear relationship
strtbuttons; percentage with the concentration of DOOS in urine;
ng to age at 1st birth however, they did have an effect on the
years of age, having urinary concentration of Cr. The effect of
<4 respectively. weight is more marked than that ofheight.
% with DOOS/Cr Fortheoretical reasons (height iscorrelated
Of ( B A <4 with lean body mass, the origin of creatin
en < 3 <4 9and its metabolite creatinine) we have pre-
25-0 60-9 anitmeaoiecetnn)wbvep-
24 7 49*4 ferred to use body-surface area which is
19 6 62-5 derived from both weight and height
2935 58 9 (Gehan & George, 1970). Fig. 4 shows the
19 8 53-6 effect of this variable.
Therefore, there is a minor effect of
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TABLE VI. DOOS/Cr ratio and paren-
chymal pattern of breast on (X-ray)
xeromammograms (dysplasia-DY; Pro-
minent duct pattern PDP) in combined
women of Cohorts I and II-IV (random
group) with no palpable breast lumps.
Cross-sections from cumalative frequency
distributions.
Paren-
chymal
pattern
Age of breast
(yrs) on X-ray
50-54 Normal
DY
PDP
55-59 Normal
DY
PDP
60-64 Normal
DY
PDP
No. of
woman
studied
995
207
54
768
141
46
556
105
42
% with DOOS/Cr
<3 <4
26-2 61-3
23-7 58-4
24-0 53-7
31-0 63-9
31-9 61-7
32-6 58-7
37-2 68-0
33-3 68-6
38-1 64-3
. MM4 t.a4_t75 .76l87t.WI&A ¢:2.0NSA
Fic. 4.-Percentages of women with urinary
an(lrogen-metabolite concentration (DOOS)
>4 mg/l and with urinary creatinine ex-
cretion > 1 g/l according to body size (body
surface area). 0, DOOS; 0 Cr.
body mass and size on the DOOS/Cr ratio.
In the analysis of possible differences be-
tween cases and controls this will be taken
into account.
Parenchymal pattern of the breast.-
Wolfe (1976) has drawn attention to the
existence of parenchymal breast patterns
seen on the mammogram which might
indicate an increased risk ofbreast cancer,
viz., those with "dysplasia" (DY) and with
a prominent duct pattern (PDP). We have
(unpublished data) some confirmatory
evidence on this point and it seemed
logical to look for any relationship be-
tween mammographic and endocrine vari-
ables.
However, as shown in Table VI, we
found no abnormal distribution of the
DOOS/Cr ratio in women showing these
mammographic images.
Case-control comparison
The prime objective of the study was
to test Bulbrook's hypothesis that andro-
gen-metabolite excretion might be of help
Note: DY and PDP sometimes co-exist. Such
mammograms have been counted as both DY and
PDP.
in selecting a high-risk group when screen-
ing a population for breast cancer.
Since 2 factors were found to have an
effect on the DOOS/Cr ratio in a 12h
urine (age and body mass or body size),
it was decided in the analysis to match for
age and to control for body-surface area
(as estimated from weight and height).
Thus in our files, for each case of breast
cancer found at screening, a matched con-
trol was found who did not differ by more
than 1 year in age with the case, and who
had been screened at about the same time
(usually the same day).
Body-surface area was estimated by
applying the formula of Gehan & George
(1970), viz.:
Body Surface Area (BSA)_
0 0235 x H0-422 x WO-514
where H height in cm and W-weight
in kg.
The results of the comparison are given
in Fig. 5 a, b, c for each age group (age at
screening) separately. No differences be-
tween cases and controls can be found in
the DOOS/Cr ratio, taking into account
their body-surface area. In the younger
E
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age group (50-54 years) there is a slight
suggestion for lower ratios in the control
group, but this is possibly due to a few
control women with large body size (and
therefore high Cr excretion).
DISCUSSION
The present study has produced mainly
negative results, in that we have not been
able to substantiate Bulbrook's hypothesis
on the possible selection of a high-risk
group on the basis of androgen metabolite
excretion.
It could be argued that our women were
somewhat older (50-64 years) than those
at Guernsey (35-55 years at entry).
Judging from the paper of Bulbrook et al.
nY
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FiT. 5. Plots of DOOS/Cr vs body surface
area in breast-cancer cases* (foundt at
screening) and controls ( ) matchedl for
age. Cases with lobular carciinoma iin situ
have been urolderline(d in the plot.
(a) Women aged 50-54.
(b) Women aged 55-59.
(c) Women aged 60-64 (60-66 years
(lurinig the course of the project).
(1971), the latter developed their cancer
when they were between 40 and 60 years
of age. Since then the number of breast
cancers found in CGuernsey has increased to
45 (Farewell et al., 1978) and the risk of
low androgen levels seems to hold for
premenopausal women only (Bulbrook,
personal communication).
For logistic reasons, 12h specimens were
used in our study instead of 24h speci-
mens. It was shown that the correlations
between the DOOS/Crratio of 12 h arid 24h
specimens are very high (r=0.95), whereas
this ratio in the 12h overnight sample
explains about 50% of the variation of
24 h excretion ofDOOS (r 0 72).
Creatinine measurements have been
introduced as a means of controlling for
individual dilution of urine. This intro-
duces a problem in so far as Cr excretion
itselfis not independent ofage and ofbody
mass or size. These variables have been
taken into account in comparing cases
with controls.
Thus our results are free of this kind of
bias.
0.0
6.0
5.0
Lz 4.0
0
o 3.0
0
2.0
1.0I
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We are aware ofthe fact that there may
be some day-to-day variation in the
excretion of both creatinine (Vestergaard,
1978) and DOOS, although both are said
to be fairly constant over time. Data are
available on 461 women in whom a second
12 h sample was collected one year later.
On the basis of urinary concentrations the
correlation coefficient between the first
and the second sample was 0 47 for DOOS
and 0'38 for Cr. The issue of variability
over time, however, is oftheoretical rather
than of practical interest when trying to
identify a high risk group in population
screening. Anxiety and stress might in-
fluence androgen-metabolite excretion.
However, the majority of the Utrecht
women screened for breast cancer for the
first time in their lives experienced a
degree of anxiety. In this respect the
women found to have breast cancer were
in the same position as the other women
who did not have the disease.
Summarizing, we have not been able to
find differences in the DOOS/Cr ratio
which could be used to identify a group
at high risk of breast cancer during a
population-screening programme offered
to a population of 50 years and over.
This does not imply that androgen
metabolism is unrelated to the risk of
breast cancer or to the course ofthedisease.
It may be that the predictive value of
androgen levels is greater in premeno-
pausal than in postmenopausal women.
For the time being, however, breast-
cancer screening is almost exclusive to the
latter group.
The authors thank Mrs A. Jongejan, Mrs S. Plomp
and Miss C. Metsemaekers and Mr B. Rademaker for
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laboratory (leterminations, Mr B. Slotboom for his
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